Hacking the cellular messenger system
Welcome. We’re EVIIVE, and we’re disrupting the diagnostics industry with our groundbreaking solutions and business ideas.
ABOUT US
We are developing novel liquid biopsies biomarkers discovery platform and assay kit provider for personalized treatment guidance and disease progression monitoring.
With our innovative and insightful technology, we strive to enhance personalized diagnostics. Founded in 2022, our incredible team of research experts have worked tirelessly to bring EVIIVE to the forefront of the Medtech industry.
We have, and will continue to work tirelessly to become the technological standard, providing big picture insights which industry leaders not only approve of, but also depend on.
Dr Kevin Yim
Co-Founder & CEO
Prof Dr Richard Chahwan
Co-Founder & CSO
OUR INNOVATIVE TECHNOLOGY
At EVIIVE, our novel technological solutions help industry leading companies and individuals achieve greater diagnostic and prognostic power. Our platform has a wide range of features that were created with an aim to help personlize patient care in a quick and effective manner. In order to empower our patients to do better, EVIIVE is continually building upon its technology, so stay in touch to learn about upgrades and other changes.
PIPELINE
Stay tuned for our upcoming pipeline
IN THE PRESS
Making Headlines
EVIIVE WINS VENTURE KICK FUNDING
28.12.2022
Startups developing a low-cost breathe ventilator, 300x faster qubits, a minimally invasive diagnostic for sepsis, sustainable real estate investment, sustainable food based on fungi and fermantation each win Venture Kick funds. News Link.
EVIIVE WINS MEDTECH FELLOWSHIP
01.06.2022
EVIIVE wins the UZH-BIOMEDTECH fellowship supported by the WSS foundation. And EVIIVE is offered lab space at IREM-Schlieren supported by the WYSS foundation. News Link.
NEW METHODOLOGY CHANGING DIAGNOSTICS
24.01.2022
Our proof of concept approach to use extracellular vesicles to detect SARS-CoV-2 infection, immune response status, and immune system effects. News Link.